NCT02477527View on ClinicalTrials.gov

Atripla to Stribild Switch Study to Evaluate Sleep Disturbances

PHASE4CompletedINTERVENTIONAL

Enrollment

21

Participants

Timeline

Start Date

February 28, 2015

Primary Completion Date

December 31, 2015

Study Completion Date

January 31, 2016

Conditions

HIVAIDSSleep Disorders

Interventions

DRUG

Stribild

Change subjects from Atripla one tablet per day to elvitegravir/ cobicistat/ emtricitabine/ tenofovir disoproxil one tablet per day.

Sponsors

Collaborators (1)

Gilead Sciences

All Listed Sponsors

collaborator

Gilead Sciences

INDUSTRY

lead

Midtown Medical Center, Tampa, FL

OTHER

NCT02477527 - Atripla to Stribild Switch Study to Evaluate Sleep Disturbances | Biotech Hunter | Biotech Hunter